Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$7.81 USD
+0.35 (4.69%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $7.80 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Terns Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 103 | 62 | 51 | 37 | 70 |
Income After Depreciation & Amortization | -103 | -62 | -50 | -37 | -70 |
Non-Operating Income | 13 | 2 | 0 | -3 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -90 | -60 | -50 | -40 | -69 |
Income Taxes | 0 | 0 | 1 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | -1 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -90 | -60 | -50 | -41 | -69 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -90 | -60 | -50 | -40 | -69 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -107 | -61 | -48 | -37 | -70 |
Depreciation & Amortization (Cash Flow) | -4 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -103 | -62 | -50 | -37 | -70 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 71.26 | 36.03 | 22.71 | 0.29 | NA |
Diluted EPS Before Non-Recurring Items | -1.27 | -1.67 | -2.21 | -102.93 | NA |
Diluted Net EPS (GAAP) | -1.27 | -1.67 | -2.21 | -102.93 | NA |
Fiscal Year end for Terns Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 25.54 | 25.45 | 24.06 | 33.18 | 21.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | -25.54 | -25.45 | -24.06 | -33.18 | -21.16 |
Non-Operating Income | 2.86 | 3.17 | 3.09 | 3.48 | 3.34 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -22.68 | -22.28 | -20.97 | -29.71 | -17.82 |
Income Taxes | 0.06 | 0.10 | 0.05 | 0.06 | 0.07 |
Minority Interest | 0.00 | -22.37 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -22.74 | -22.37 | -21.02 | -29.77 | -17.90 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -22.74 | -22.37 | -21.02 | -29.77 | -17.90 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 74.46 | 74.40 | 72.33 | 71.53 | 71.36 |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.30 | -0.29 | -0.42 | -0.25 |
Diluted Net EPS (GAAP) | -0.31 | -0.30 | -0.29 | -0.42 | -0.25 |